The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent;
wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

Nanoparticles comprising resiniferatoxin (RTX) encapsulated in a poly(lactic-co-glycolic acid) (PLGA) polymer and compositions, especially topical compositions, comprising the nanoparticles. The compositions can be used as topical formulations for ameliorating pain, including for diabetic patients with peripheral neuropathy.

The composition is a hydrogel which may be used to deliver therapeutics vaginally. The hydrogel may include a glycosaminoglycan. The glycosaminoglycan may include multiple thiol groups. The composition may also include a molecule that includes at least two thiol reactive sites. The composition may include a mucoadhesive agent as well as a therapeutic agent. The composition may deliver the therapeutic at a pH that is optimal for the vaginal environment, namely between about 3.5 and 5.0.

Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.

Dissolvable unit dose film constructs are made by providing a muco-adhesive composition including a muco-adhesive polymer matrix in which the muco-adhesive polymer matrix has a water-soluble polymer, water-dispersible polymer, water-swellable polymer, or combinations thereof and a liquid carrier. The method further includes drying the muco-adhesive composition to remove at least a portion of the liquid carrier, forming a muco-adhesive film substrate, forming a composition for an active layer, the composition including a polymer matrix in which the polymer matrix for the active layer composition includes a water-soluble polymer, water-dispersible polymer, water-swellable polymer, or combinations thereof, an active ingredient and a liquid carrier. The method further includes depositing the composition for the active layer onto the muco-adhesive substrate as a plurality of individual volumes and removing the liquid carrier from the plurality of deposited individual volumes to form a plurality of dissolvable film active layers on the muco-adhesive substrate.

An encapsulated bacteriophage formulation and a method for encapsulating bacteriophages and bacteriophage-related products in polymeric microcapsules is provided. Some embodiments of the method of producing the encapsulated bacteriophages involves a water-in-oil-in-water double emulsion.

Provided is a composition for forming a coating film directly on the skin by an electrostatic spray, the composition being capable of forming a coating film having excellent skin compatibility, adhesion, and scratch resistance, having a good feel, and being easy to peel. A composition for forming a coating film, for forming a coating film composed of fibers directly on the skin by an electrostatic spray, the composition comprising the following Components (a), (b), (c), and (d): (a) a polymer having a coating film forming ability (b) one or more volatile substances selected from the group consisting of an alcohol and a ketone (c) a plasticizer (d) a feel modifier other than Component (c).

The invention relates to a sprayable liquid solution for the transdermal delivery of testosterone comprising testosterone, a penetration enhancer, and a film forming excipient, and to methods of treatment using this composition.

Hemostatic compositions including a combination of more than one hemostatic agent, and devices coated or impregnated therewith, have been developed. Nanotechnology yields hemostatic agents with large surface areas thereof, thereby increasing the hemostatic properties of the device to which they are applied. By combining more than one hemostatic agent and utilizing one or more different nanotechnology approaches to enhance the surface areas thereof, the capability of the dressing to stop bleeding is improved via more than one mechanism, and thus provides better hemostasis.

An external skin preparation comprises the following components (A) to (E), wherein the mass ratio of the component (A) to the component (B), (A)/(B), is from 0.3 to 2.0, wherein the content of the component (C) is from 0.1 to 1 mass %, and wherein the preparation has a pH at 25° C. of from 4.0 to 7.0: (A) one or more selected from the group consisting of aliphatic alcohols having from 14 to 20 carbon atoms; (B) two or more selected from the group consisting of polyhydric alcohol fatty acid ester-type nonionic surfactants; (C) one or more selected from the group consisting of N-acyl amino acids, N-acyl taurine, salts thereof, and phospholipids; (D) one or more selected from the group consisting of steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory drugs, and heparinoids; and (E) water.